Velinotamig for Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia
What You Need to Know Before You Apply
What is the purpose of this trial?
A Phase 1b/2a, open-label dose escalation and dose expansion study of subcutaneously (SC) administered velinotamig for the treatment of adults with relapsing and refractory immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) to evaluate safety and tolerability.
Are You a Good Fit for This Trial?
This trial is for adults who have immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has come back or hasn't improved with previous treatments.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Velinotamig
Trial Overview
The study is testing different doses of a new drug called velinotamig, given as an injection under the skin, to see if it is safe and well-tolerated in people with relapsed or hard-to-treat ITP or wAIHA.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Patients with relapsing and refractory immune thrombocytopenia and warm autoimmune hemolytic anemia with velinotamig in dose expansion cohorts.
Patients with relapsing and refractory immune thrombocytopenia and warm autoimmune hemolytic anemia with velinotamig in dose escalation cohorts.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cullinan Therapeutics Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.